All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-PSCA chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human PSCA. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-PSCA antibody linked to CD3ζ signaling domains. And the vector product was designed for the treatment of Pancreatic cancer.
CAR Construction : Ha1-4.117 scFv-CD28-4-1BB-CD3ζ
Fig.1 FACS analysis of CAR expression in primary human T cells. OKT3-stimulated peripheral blood mononuclear cells were transduced twice with retroviral vectors encoding the indicated CAR constructs. A Herceptin-based anti-Her2/neu CAR was used as a positive control. SA-PE: cells incubated with secondary staining (streptavidin-PE) alone as isotype control. Abate-Daga, D., Lagisetty, K. H., Tran, E., Zheng, Z., Gattinoni, L., Yu, Z., ... & Morgan, R. A. (2014). A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Human gene therapy, 25(12), 1003-1012. |
CAR Construction : Ha1-4.117 scFv-CD28-4-1BB-CD3ζ
Fig.2 Surface expression of anti-PSCA and anti-MSLN CARs. Histograms showing results of protein-L staining, analyzed by FACS, of primary human T lymphocytes engineered to express the two Abate-Daga, D., Lagisetty, K. H., Tran, E., Zheng, Z., Gattinoni, L., Yu, Z., ... & Morgan, R. A. (2014). A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Human gene therapy, 25(12), 1003-1012. |
CAR Construction : Ha1-4.117 scFv-CD28-4-1BB-CD3ζ
Fig.3 Immunohistochemistry staining of PSCA CAR-treated tumors. Immunohistochemistry of tumor sections showing strong PSCA staining in control groups and greatly reduced staining in PSCA CAR-treated mice. Scale bars represent 2000 lm in the top row and 200 lm in the bottom row. Abate-Daga, D., Lagisetty, K. H., Tran, E., Zheng, Z., Gattinoni, L., Yu, Z., ... & Morgan, R. A. (2014). A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Human gene therapy, 25(12), 1003-1012. |
CAR Construction : Ha1-4.117 scFv-CD28-4-1BB-CD3ζ
Fig.4 PSCA CARs effectively treat established tumors in NSG mice. Growth curves after treatment with CARexpressing human T cells or controls, in two independent experiments. Abate-Daga, D., Lagisetty, K. H., Tran, E., Zheng, Z., Gattinoni, L., Yu, Z., ... & Morgan, R. A. (2014). A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Human gene therapy, 25(12), 1003-1012. |
CAR Construction : Ha1-4.117 scFv-CD28-4-1BB-CD3ζ
Fig.5 Flow cytometry analysis of CD69 and CD25 abundance on preinfusion (day 12) CD8+ T cells that expressed GFP or CARs, as indicated. Histograms are representative of 4 independent experiments. Ramello, M. C., Benzaïd, I., Kuenzi, B. M., Lienlaf-Moreno, M., Kandell, W. M., Santiago, D. N., ... & Abate-Daga, D. (2019). An immunoproteomic approach to characterize the CAR interactome and signalosome. Science signaling, 12(568), eaap9777. |
CAR Construction : Ha1-4.117 scFv-CD28-4-1BB-CD3ζ
Fig.6 Western blot analysis of CD3ζ interaction in lysates of T cells transduced with PSCA-28t28Z, PSCA-8t28BBZ, or GFP and immunoprecipitated for the CAR scFv. Data are represented as mean±s.d. Ramello, M. C., Benzaïd, I., Kuenzi, B. M., Lienlaf-Moreno, M., Kandell, W. M., Santiago, D. N., ... & Abate-Daga, D. (2019). An immunoproteomic approach to characterize the CAR interactome and signalosome. Science signaling, 12(568), eaap9777. |
CAR Construction : Ha1-4.117 scFv-28ζ
Fig.7 Flow cytometry analysis of CAR abundance on PSCA-8t28Z (green) and PSCA-8t(+24)28Z (light blue) and GFP (gray)-transduced T cells. Histograms (left) are representative of 5 independent experiments. Ramello, M. C., Benzaïd, I., Kuenzi, B. M., Lienlaf-Moreno, M., Kandell, W. M., Santiago, D. N., ... & Abate-Daga, D. (2019). An immunoproteomic approach to characterize the CAR interactome and signalosome. Science signaling, 12(568), eaap9777. |
CAR Construction : Ha1-4.117 scFv-28ζ
Fig.8 Western blot analysis of CD3ζ interaction in lysates of T cells transduced with PSCA-28t28Z, PSCA-8t28BBZ, or GFP and immunoprecipitated for the CAR scFv. Data are represented as mean±s.d. Ramello, M. C., Benzaïd, I., Kuenzi, B. M., Lienlaf-Moreno, M., Kandell, W. M., Santiago, D. N., ... & Abate-Daga, D. (2019). An immunoproteomic approach to characterize the CAR interactome and signalosome. Science signaling, 12(568), eaap9777. |
CAR Construction : Ha1-4.117 scFv-28ζ
Fig.9 CAR signaling upon antigen binding. Proteomics data analysis of the 40/751 phospho-proteins that were differentially abundant in CAR-T cells when compared to Ramello, M. C., Benzaïd, I., Kuenzi, B. M., Lienlaf-Moreno, M., Kandell, W. M., Santiago, D. N., ... & Abate-Daga, D. (2019). An immunoproteomic approach to characterize the CAR interactome and signalosome. Science signaling, 12(568), eaap9777. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-PSCA (Ha1-4.117 ) h(CD3ζ) CAR, pCDCAR1 (CAR-MZ038). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION